Arcutis to Present Multiple Abstracts at Alopecia, Vitiligo, and Eczema Conference

Arcutis Biotherapeutics, Inc., a company specializing in immuno-dermatology, announced the presentation of key clinical data at the upcoming Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago from June 8-10, 2024. The conference will feature five abstracts from the company. Notably, new long-term safety and efficacy data of investigational roflumilast cream 0.15% for patients aged six and older with mild to moderate atopic dermatitis will be presented. Additionally, preclinical data on ARQ-234, a CD200 receptor agonist for atopic dermatitis, will be highlighted.

Arcutis’ Chief Medical Officer, Dr. Patrick Burnett, emphasized the company’s commitment to advancing treatment options for chronic immune-mediated skin diseases. He highlighted the significance of the data to be presented, particularly for the roflumilast cream used in their INTEGUMENT program, which targets both adults and children with atopic dermatitis. He also mentioned preclinical data on ARQ-234, a biologic under development for atopic dermatitis.

The conference will feature an oral poster presentation titled "Long-term Safety and Efficacy of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis.” This presentation, led by Dr. Melinda Gooderham, will unveil findings from a 52-week, Phase 3, open-label safety trial.

In addition to this, several electronic posters will be accessible throughout the conference and online starting June 8, 2024. These include:

1. Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15%: This ePoster will provide comprehensive data from the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 clinical trials, focusing on both adults and children with atopic dermatitis.

2. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients: This ePoster will present findings from a Phase 3 randomized controlled trial (INTEGUMENT-PED) evaluating the efficacy and safety of roflumilast cream in pediatric patients aged 2 to 5 years with mild to moderate atopic dermatitis.

3. ARQ-234: a High Affinity CD200-Fc Fusion Protein for Atopic Dermatitis: This ePoster will feature preclinical data on ARQ-234, a novel therapeutic approach for atopic dermatitis.

4. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast: This ePoster will discuss the local tolerability profile of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.

Arcutis Biotherapeutics, Inc. is known for its innovative approaches in medical dermatology, addressing the needs of patients with inflammatory skin conditions. The company has a diverse portfolio, including FDA-approved products and a robust pipeline targeting conditions like scalp and body psoriasis, atopic dermatitis, and alopecia areata.

One of the company’s notable products, ZORYVE, is indicated for the treatment of plaque psoriasis and seborrheic dermatitis. The product's safety profile includes common adverse reactions such as diarrhea, headaches, and upper respiratory tract infections for the cream formulation, and nasopharyngitis, nausea, and headaches for the foam formulation. The company advises caution due to the flammability of the foam formulation and contraindications for patients with moderate to severe liver impairment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!